Amaç: Kuru göz hastalarında, topikal siklosporin tedavisinin gözyaşı, menisküs parametreleri ve oküler yüzey boyanması üzerine olan etkisini değerlendirmek. Gereç ve Yöntemler: Bu prospektif çalışmaya 20 sağlıklı birey ve 18 kuru göz hastası dâhil edildi. Kuru göz tanısı alan hastalara, günde 2 kez %0,05 siklosporin A tedavisi başlandı. Tedavi öncesi ve tedavi sonrası (1. ay, 2. ay, 3. ay) Schirmer testi, gözyaşı kırılma zamanı (GKZ), Oküler Yüzey Hastalık İndeksi (OSDI) anketi, oküler yüzey boyanma testleri (floresein ve lisamin yeşili) ve alt gözyaşı menisküs parametre ölçümleri yapıldı. Alt gözyaşı parametrelerinden, gözyaşı menisküs yüksekliği (GMY), gözyaşı menisküs derinliği (GMD) ve gözyaşı menisküs alanı (GMA) Optik koherens tomografi (OKT) ile ölçüldü. Bulgular: Hastaların yaş ortalamaları (p=0,06) ve cinsiyet dağılımları (p=0,48) açısından gruplar arasında istatistiksel olarak anlamlı fark bulunmadı. Tedavi öncesi, ortalama Schirmer testi ve GKZ değerleri kuru göz grubunda daha düşüktü (p0,05). GMA değerlerinin tedavi sonrası zaman içindeki değişimi anlamlı idi (p=0,01). Sonuç: Schirmer testi, GKZ ve oküler boyanma skorları kuru göz tanısının konulmasında kullanılabilecek invaziv yöntemlerdir. OKT ile ölçülen alt gözyaşı menisküs parametreleri, kuru göz hastalarının tanısında, değerli, hızlı ve invaziv olmayan bir tanı yöntemi olabileceği gibi topikal siklosporin tedavisinin etkinliğini değerlendirmede de kullanılabilir.
Anahtar Kelimeler: Gözyaşı menisküs yüksekliği; kuru göz; topikal siklosporin damla
Objective: To evaluate the effect of topical cyclosporine treatment on tear meniscus parameters and ocular surface staining in patients with dry eye disease. Material and Methods: Twenty normal subjects and 18 dry eye patients were enrolled to this prospective study. Patients with dry eye were instructed to use topical cyclosporine A 0.05% twice a day. Pre- and post treatment (1, 2, 3 months) measurements included Ocular Surface Discomfort Index (OSDI) score, Schirmer test, tear break-up time (TBUT), ocular surface vital staining (fluorescein and lissamine green), and lower tear meniscus parameters. Lower tear meniscus parameters of tear meniscus height (TMH), depth (TMD) and area (TMA) were measured using optical coherence tomography (OCT). Results: No significant differences were observed in age (p=0.06) and gender (p=0.48) between the groups. The mean of Schirmer test and TBUT was significantly decreased in patients with dry eye (p0.05). There was no statistically significant increase in GMA values at the first and second months of treatment, but at the end of the third month there was a significant increase (p=0.01). Conclusion: Schirmer test, TBUT, and ocular staining scores are invasive methods that can be used to diagnose dry eye. Lower tear meniscus parameters obtained by OCT can be used as a valuable, quick, non-invasive test for diagnosing dry eye as well as monitoring the effect of topical cyclosporine treatment.
Keywords: Tear meniscus height; dry eye; topical cyclosporine drop
- Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3): 438-510. [Crossref] [PubMed]
- Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3): 276-83. [Crossref] [PubMed]
- Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539-74. [Crossref] [PubMed]
- Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628. [Crossref] [PubMed]
- Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802-12. [Crossref] [PubMed]
- Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321-38. [Crossref] [PubMed]
- Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology. 2000;107(4):631-9. [Crossref]
- Shen M, Li J, Wang J, Ma H, Cai C, Tao A, et al. Upper and lower tear menisci in the diagnosis of dry eye. Invest Ophthalmol Vis Sci. 2009;50(6) 2722-6. [Crossref] [PubMed]
- Yuan Y, Wang J, Chen Q, Tao A, Shen M, Shousha MA, et al. Reduced tear meniscus dynamics in dry eye patients with aqueous tear deficiency. Am J Ophthalmol. 2010; 149(6):932-8.e1. [Crossref] [PubMed] [PMC]
- Wang J, Aquavella J, Palakuru J, Chung S. Repeated measurements of dynamic tear distribution on the ocular surface after instillation of artificial tears. Invest Ophthalmol Vis Sci. 2006;47(8):3325-9. [Crossref] [PubMed] [PMC]
- Chen F, Shen M, Chen W, Wang J, Li M, Yuan Y, et al. Tear meniscus volume in dry eye after punctal occlusion. Invest Ophthalmol Vis Sci. 2010;51(4):1965-9. [Crossref] [PubMed]
- Lemp MA. Report of the National eye ınstitute/ındustry workshop on clinical trials in dry eyes. CLAO J. 1995;21(4):221-32.
- Mainstone JC, Bruce AS, Golding TR. Tear meniscus measurement in the diagnosis of dry eye. Curr Eye Res. 1996;15(6):653-61. [Crossref] [PubMed]
- Golding TR, Bruce AS, Mainstone JC. Relationship between tear-meniscus parameters and tear-film breakup. Cornea. 1997;16(6):649-61. [Crossref]
- Fodor E, Hagyo K, Resch M, Somodi D, Nemeth J. Comparison of tearscope-plus versus slit lamp measurements of inferior tear meniscus height in normal individuals. Eur J Ophthalmol. 2010;20(5):819-24. [Crossref] [PubMed]
- Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin a phase 2 study group. Ophthalmology. 2000;107(5):967-74. [Crossref]
- Wang J, Cui L, Shen M, Perez VL, Wang MR. Ultra-high resolution optical coherence tomography for monitoring tear meniscus volume in dry eye after topical cyclosporine treatment. Clin Ophthalmol. 2012;6:933-8. [Crossref] [PubMed] [PMC]
- Demirok GS, Gürdal C, Saraç Ö, Ceran BB, Can İ. [Eveluating of tear meniscus parameters with optical coherent tomography in dry-eye patients].Turk J Ophthalmol. 2013;43:258-62.
- Altan-Yaycioglu R, Sizmaz S, Canan H, Coban-Karatas M. Optical coherence tomography for measuring the tear film meniscus: correlation with schirmer test and tear-film breakup time. Curr Eye Res. 2013;38(7):36-742. [Crossref] [PubMed]
- Czajkowski G, Kaluzny BJ, Laudencka A, Malukiewicz G, Kaluzny JJ. Tear meniscus measurement by spectral optical coherence tomography. Optom Vis Sci. 2012;89(3):336-42. [Crossref] [PubMed]
- Li M, Du C, Zhu D, Shen M, Cui L,Wang J, et al. Daytime variations of tear osmolarity and tear meniscus volume. Eye Contact Lens. 2012;38(5):282-7. [Crossref] [PubMed] [PMC]
- Tung CI, Kottaiyan R, Koh S, Wang Q, Yoon G, Zavislan JM, et al. Noninvasive, objective, multimodal tear dynamics evaluation of 5 over-the-counter tear drops in a randomized controlled trial. Cornea. 2012;31(2):108-14. [Crossref] [PubMed]
- Sahlin S, Chen E. Gravity, blink rate, and lacrimal drainage capacity. Am J Ophthalmol. 1997;124(6):758-64. [Crossref]
.: İşlem Listesi